Anzeige
Mehr »
Mittwoch, 01.10.2025 - Börsentäglich über 12.000 News
Globaler Gamechanger: CiTech expandiert in Europa - neue Chancen für Investoren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40RNN | ISIN: US13463J1016 | Ticker-Symbol:
NASDAQ
30.09.25 | 21:59
3,000 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CAMP4 THERAPEUTICS CORP Chart 1 Jahr
5-Tage-Chart
CAMP4 THERAPEUTICS CORP 5-Tage-Chart

Aktuelle News zur CAMP4 THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14:26Camp4 Therapeutics Corp - 8-K, Current Report1
14:18CAMP4 Therapeutics begins toxicology studies for SYNGAP1 therapy1
14:06CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-0125CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory...
► Artikel lesen
CAMP4 THERAPEUTICS Aktie jetzt für 0€ handeln
16.09.JPMorgan downgrades CAMP4 Therapeutics stock to Neutral on long timeline1
15.09.CAMP4 Therapeutics stock price target lowered to $12 at Piper Sandler1
15.09.Piper Sandler senkt Kursziel für CAMP4 Therapeutics auf 12 US-Dollar1
10.09.CAMP4 Therapeutics stock soars after $100 million private placement4
10.09.CAMP4 Therapeutics: CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders4
10.09.Camp4 Therapeutics Corp - 8-K, Current Report3
15.08.Camp4 Therapeutics GAAP EPS of -$0.62 beats by $0.06, revenue of $1.5M beats by $1.2M1
13.06.Camp4 Therapeutics Corp - 8-K, Current Report1
27.05.Wedbush bewertet CAMP4-Aktie mit "Outperform" und setzt Kursziel bei 8 US-Dollar1
16.05.CAMP4 Therapeutics: CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders ...1
13.05.Camp4 Therapeutics Corp - 10-Q, Quarterly Report1
13.05.Camp4 Therapeutics Corp - 8-K, Current Report1
13.05.CAMP4 Therapeutics: CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights207Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD) cohort 3; safety, pharmacokinetic, and pharmacodynamic data expected...
► Artikel lesen
02.05.Pre-market Movers: Classover Holdings, Block, Inc., Advantage Solutions, Ardelyx, CAMP4 Therapeutics977CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green Classover Holdings, Inc. (KIDZ) is up over 65% at...
► Artikel lesen
28.04.CAMP4 Therapeutics: CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting1
27.03.CAMP4 Therapeutics: CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update261- Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in two of four multiple ascending dose (MAD) cohorts; safety, pharmacokinetic, and pharmacodynamic...
► Artikel lesen
07.01.CAMP4 Therapeutics: CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones323Data from Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 for the treatment of urea cycle disorders (UCDs) demonstrates favorable safety resultsCompleted dosing in the first two...
► Artikel lesen
Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1